Evolut Low News Today

Nearly all of our most-read articles on TCTMD this month stemmed from TCT 2023, with two notable outliers.

Intermediate-term reports from PARTNER 3 and Evolut Low Risk trials

June 09, 2021 Transcatheter aortic valve implantation is approved in the United States for low-risk patients with severe aortic stenosis, without an age threshold. As the authors of a new review point out, though, much is still unknown about how youth can impact outcomes and future options. Low risk and younger age are categories that should not be conflated, they urge. “The pivotal TAVR trials in low-risk patients have, so far, demonstrated excellent clinical outcomes. However, these results...

Medtronic Evolut TAVI Now Licensed for Both Bicuspid Aortic Valves at Intermediate or Greater Risk and for Low Risk of Surgical Mortality Health Canada Issues Licence for Expanded Indications for Evolut TAVI Platform  Medtronic Canada ULC, a subsidiary of Medtronic plc ― the world’s largest medical technology, services, and solutions company ― has received a new expanded indication from Health Canada for its Evolut™ Transcatheter Aortic Valve Implantation system. Medtronic’s TAVI pla...